FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2160872671> ?p ?o ?g. }

• W2160872671 endingPage "326" @default.
• W2160872671 startingPage "318" @default.
• W2160872671 abstract "Purpose To describe the minimum inhibitory concentration (MIC) of fungal isolates to natamycin and voriconazole, and to compare these MICs to previous ocular susceptibility studies. Design Experimental laboratory study using isolates from a randomized clinical trial. Methods The Mycotic Ulcer Treatment Trial I was a randomized, double-masked, multicenter trial comparing topical natamycin and voriconazole for fungal keratitis treatment. Susceptibility testing to natamycin and voriconazole were performed according to Clinical and Laboratory Standards Institute methods. The relationship between organism and MIC was assessed. A literature review was performed to compare results to previous ocular susceptibility studies. Results Of the 323 patients enrolled in the trial, MICs were available for 221 (68%). Fusarium (n = 126) and Aspergillus species (n = 52) were the most commonly isolated organisms. MICs to natamycin and voriconazole were significantly different across all genera (P < .001). The MIC median (MIC50) and 90th percentile (MIC90) for natamycin were equal to or higher than voriconazole for all organisms except Curvularia species. Compared to other organisms, Fusarium species isolates had the highest MICs to voriconazole and Aspergillus flavus isolates had the highest MICs to natamycin. Our results were similar to previous reports except that the voriconazole MIC90 against Aspergillus species was 2-fold higher and the natamycin MIC90 against Aspergillus fumigatus was 4-fold higher in our study. Conclusion In this large susceptibility study, Fusarium isolates were least susceptible to voriconazole and A flavus isolates were least susceptible to natamycin when compared to other filamentous fungi. In the future, susceptibility testing may help guide therapy if performed in a timely manner. To describe the minimum inhibitory concentration (MIC) of fungal isolates to natamycin and voriconazole, and to compare these MICs to previous ocular susceptibility studies. Experimental laboratory study using isolates from a randomized clinical trial. The Mycotic Ulcer Treatment Trial I was a randomized, double-masked, multicenter trial comparing topical natamycin and voriconazole for fungal keratitis treatment. Susceptibility testing to natamycin and voriconazole were performed according to Clinical and Laboratory Standards Institute methods. The relationship between organism and MIC was assessed. A literature review was performed to compare results to previous ocular susceptibility studies. Of the 323 patients enrolled in the trial, MICs were available for 221 (68%). Fusarium (n = 126) and Aspergillus species (n = 52) were the most commonly isolated organisms. MICs to natamycin and voriconazole were significantly different across all genera (P < .001). The MIC median (MIC50) and 90th percentile (MIC90) for natamycin were equal to or higher than voriconazole for all organisms except Curvularia species. Compared to other organisms, Fusarium species isolates had the highest MICs to voriconazole and Aspergillus flavus isolates had the highest MICs to natamycin. Our results were similar to previous reports except that the voriconazole MIC90 against Aspergillus species was 2-fold higher and the natamycin MIC90 against Aspergillus fumigatus was 4-fold higher in our study. In this large susceptibility study, Fusarium isolates were least susceptible to voriconazole and A flavus isolates were least susceptible to natamycin when compared to other filamentous fungi. In the future, susceptibility testing may help guide therapy if performed in a timely manner." @default.
• W2160872671 created "2016-06-24" @default.
• W2160872671 creator A5009715006 @default.
• W2160872671 creator A5044267307 @default.
• W2160872671 creator A5054709225 @default.
• W2160872671 creator A5056040504 @default.
• W2160872671 creator A5066257890 @default.
• W2160872671 creator A5080095497 @default.
• W2160872671 creator A5081178822 @default.
• W2160872671 creator A5083977951 @default.
• W2160872671 creator A5084428982 @default.
• W2160872671 creator A5091117608 @default.
• W2160872671 date "2014-02-01" @default.
• W2160872671 modified "2023-10-03" @default.
• W2160872671 title "In Vitro Susceptibility of Filamentous Fungal Isolates From a Corneal Ulcer Clinical Trial" @default.
• W2160872671 cites W1570211125 @default.
• W2160872671 cites W1592505922 @default.
• W2160872671 cites W1612557713 @default.
• W2160872671 cites W1942594925 @default.
• W2160872671 cites W1966326401 @default.
• W2160872671 cites W1991950950 @default.
• W2160872671 cites W1998209502 @default.
• W2160872671 cites W2001276323 @default.
• W2160872671 cites W2029724631 @default.
• W2160872671 cites W2033766574 @default.
• W2160872671 cites W2036030199 @default.
• W2160872671 cites W2042213457 @default.
• W2160872671 cites W2048648390 @default.
• W2160872671 cites W205913921 @default.
• W2160872671 cites W2060343335 @default.
• W2160872671 cites W2069702799 @default.
• W2160872671 cites W2070165606 @default.
• W2160872671 cites W2091330203 @default.
• W2160872671 cites W2093065084 @default.
• W2160872671 cites W2098256719 @default.
• W2160872671 cites W2098654234 @default.
• W2160872671 cites W2102905203 @default.
• W2160872671 cites W2110459852 @default.
• W2160872671 cites W2113040118 @default.
• W2160872671 cites W2118836068 @default.
• W2160872671 cites W2122650809 @default.
• W2160872671 cites W2127059740 @default.
• W2160872671 cites W2133800972 @default.
• W2160872671 cites W2145621004 @default.
• W2160872671 cites W2148159788 @default.
• W2160872671 cites W2148800293 @default.
• W2160872671 cites W2152310572 @default.
• W2160872671 cites W2156509535 @default.
• W2160872671 cites W2157088595 @default.
• W2160872671 cites W2157444366 @default.
• W2160872671 cites W2159093932 @default.
• W2160872671 cites W2160234801 @default.
• W2160872671 cites W2165724966 @default.
• W2160872671 cites W4237275920 @default.
• W2160872671 cites W79174299 @default.
• W2160872671 doi "https://doi.org/10.1016/j.ajo.2013.10.004" @default.
• W2160872671 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3896887" @default.
• W2160872671 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24439440" @default.
• W2160872671 hasPublicationYear "2014" @default.
• W2160872671 type Work @default.
• W2160872671 sameAs 2160872671 @default.
• W2160872671 citedByCount "49" @default.
• W2160872671 countsByYear W21608726712014 @default.
• W2160872671 countsByYear W21608726712015 @default.
• W2160872671 countsByYear W21608726712016 @default.
• W2160872671 countsByYear W21608726712017 @default.
• W2160872671 countsByYear W21608726712018 @default.
• W2160872671 countsByYear W21608726712019 @default.
• W2160872671 countsByYear W21608726712020 @default.
• W2160872671 countsByYear W21608726712021 @default.
• W2160872671 countsByYear W21608726712022 @default.
• W2160872671 countsByYear W21608726712023 @default.
• W2160872671 crossrefType "journal-article" @default.
• W2160872671 hasAuthorship W2160872671A5009715006 @default.
• W2160872671 hasAuthorship W2160872671A5044267307 @default.
• W2160872671 hasAuthorship W2160872671A5054709225 @default.
• W2160872671 hasAuthorship W2160872671A5056040504 @default.
• W2160872671 hasAuthorship W2160872671A5066257890 @default.
• W2160872671 hasAuthorship W2160872671A5080095497 @default.
• W2160872671 hasAuthorship W2160872671A5081178822 @default.
• W2160872671 hasAuthorship W2160872671A5083977951 @default.
• W2160872671 hasAuthorship W2160872671A5084428982 @default.
• W2160872671 hasAuthorship W2160872671A5091117608 @default.
• W2160872671 hasBestOaLocation W21608726712 @default.
• W2160872671 hasConcept C16005928 @default.
• W2160872671 hasConcept C176947019 @default.
• W2160872671 hasConcept C2776079991 @default.
• W2160872671 hasConcept C2777292910 @default.
• W2160872671 hasConcept C2778560704 @default.
• W2160872671 hasConcept C2778867309 @default.
• W2160872671 hasConcept C2779117757 @default.
• W2160872671 hasConcept C2779175654 @default.
• W2160872671 hasConcept C2779548794 @default.
• W2160872671 hasConcept C2779787849 @default.
• W2160872671 hasConcept C2780690907 @default.
• W2160872671 hasConcept C31903555 @default.
• W2160872671 hasConcept C501593827 @default.
• W2160872671 hasConcept C59822182 @default.

• next